Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis-Reference-Cited by-同舟云学术

Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis

Published:2021-11 Issue: Volume:188 Page:106602
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Aul Dr Raminder,Gates Dr Jessica,Draper Dr Adrian,Dunleavy Dr Anne,Ruickbie Dr Sachelle,Meredith Dr Helen,Walters Dr Nicola,van Zeller Dr Cristiano,Taylor Dr Victoria,Bridgett Dr Michael,Dunwoody Dr Roisin,Grubnic Dr Sisa,Jacob Dr Tersesa,Ean Ong Dr Yee

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference50 articles.

1. An interactive web-based dashboard to track COVID-19 in real time;Dong;Lancet Infect. Dis.,2020

2. Dexamethasone in hospitalized patients with covid-19 — preliminary report;N. Engl. J. Med.,2020

3. Compassionate use of remdesivir for patients with severe covid-19;Grein;N. Engl. J. Med.,2020

4. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial;Wang;Lancet,2020

5. Follow-up studies in COVID-19 recovered patients - is it mandatory?;Balachandar;Sci. Total Environ.,2020

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effects of COVID-19 severity on health status in Kazakhstan: A prospective cohort study;Clinical Epidemiology and Global Health;2024-09

2. Evaluation of Long-Coronavirus Disease 2019 Cases Readmitted to Intensive Care Units Due to Acute Respiratory Failure: Point Prevalence Study;Thoracic Research and Practice;2024-08-02

3. Prospects for the Protective Mechanisms and Compounds of Bufei Huoxue Capsule against COVID-19 Convalescence: Evaluation of Integrating UHPLC-HRMS Analysis and Network Pharmacology Strategy;Combinatorial Chemistry & High Throughput Screening;2024-06-12

4. COVID-19 Chest Manifestation on CT Scan and Associated Risk Factors for Developing Pulmonary Fibrosis;Cureus;2024-03-21

5. Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers;International Journal of Molecular Sciences;2024-01-26